Central Precocious Puberty Market
- 2026 年市場規模
- USD 2,164.7 Mn
- 2033 年預估規模
- USD 3,685.4 Mn
- 年複合成長率 CAGR
- 7.9%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Central Precocious Puberty Market, By Drug (Leuprolide Acetate, Triptorelin, Histrelin Acetate, Nafarelin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
報告摘要
Gonadotropin-releasing hormone (GnRH) agonist are potential treatment options for the CPP as they inhibit stimulation effects of endogenous GnRH and accelerate bone maturation, thereby suppressing early puberty. GnRH therapy delays the onset of puberty leading to delay in menarche Triptodor (triptorelin), Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) are approved treatment medications available in the market for central precocious puberty (CPP). Moreover, Triptodur, Lupron Depot-Ped, and Supprelin LA are Gonadotropin-releasing hormone (GnRH) agonists used to prolong the suppression of gonadotropin secretion when required. Triptorelin, a GnRH agonist, effectively suppresses the pituitary-gonadal axis and pubertal development in children with CPP.
Market Dynamics
Reimbursement for the treatment of central precocious puberty is provided through Medicaid, which is expected to offer lucrative growth opportunities for the global central precocious puberty market during the forecast period. According to N.C. Medicaid Bulletin December 2017, Triptodur: an extended-release injectable suspension for intramuscular use, operates under Medicaid Healthcare Common Procedure Coding System (HCPCS) code J3490. According to the same source, from September 2017, N.C. Medicaid and N.C. Health Choice (NCHC) programs cover triptorelin extended-release injectable suspension for intramuscular use (Triptodur) for use in the Physician's Drug Program (PDP). For Medicaid and NCHC billing, the maximum reimbursement rate per unit of Triptodur is: US$ 17,280.00 per kit.
Key features of the study
• This report provides an in-depth analysis of the global central precocious puberty market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this marke
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global central precocious puberty market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global central precocious puberty market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global central precocious puberty market
Market Segmentation
• By Drug (Revenue, USD Mn, 2021-2033)
o Leuprolide Acetate
o Triptorelin
o Histrelin Acetate
o Nafarelin
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Central Precocious Puberty Market, By Region (Revenue, USD Mn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Teva Pharmaceutical Industries Ltd.
o AbbVie Inc.
o Arbor Pharmaceuticals, LLC
o Pfizer Inc.
o Tolmar Pharmaceuticals, Inc.
o Endo International plc
o Ipsen Pharma
o Debiopharm Group
o Sun Pharmaceutical Industries Limited
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Central Precocious Puberty Market, By Drug, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Leuprolide Acetate
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Triptorelin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Histrelin Acetate
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Nafarelin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
5. Global Central Precocious Puberty Market, By Distribution Channel, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
6. Global Central Precocious Puberty Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AbbVie Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Arbor Pharmaceuticals, LLC
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Tolmar Pharmaceuticals, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Endo International plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ipsen Pharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Debiopharm Group
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Sun Pharmaceutical Industries Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們